KRAS and colorectal carcinoma: CRC-NK cells also exhibited altered antibody-dependent cellular cytotoxicity (ADCC) function responding poorly to cetuximab, which in addition to inhibiting the proliferation of K-RAS wild-type tumor cells (24), mediates ADCC performed by NK cells through CD16 Fcγ receptor, which has been strongly associated to cetuximab response in CRC (25).